Harbeck N - Search Results

1

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators. Harbeck N, et al. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31. Breast Cancer Res Treat. 2017. PMID: 27798749 Free PMC article. Clinical Trial.

2

[Possibilities in immunocytochemistry exemplified by bone marrow aspiration cytology in patients with breast carcinoma].

Eiermann W, Harbeck N, Untch M. Eiermann W, et al. Among authors: harbeck n. Gynakologe. 1990 Dec;23(6):358-64. Gynakologe. 1990. PMID: 2177719 German. No abstract available.

3

[Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?].

Untch M, Harbeck N, Eiermann W. Untch M, et al. Among authors: harbeck n. Gynakol Rundsch. 1989;29 Suppl 2:231-3. Gynakol Rundsch. 1989. PMID: 2693244 German. No abstract available.

4

Micrometastases in bone marrow in patients with breast cancer.

Untch M, Harbeck N, Eiermann W. Untch M, et al. Among authors: harbeck n. Br Med J (Clin Res Ed). 1988 Jan 23;296(6617):290. doi: 10.1136/bmj.296.6617.290. Br Med J (Clin Res Ed). 1988. PMID: 3124916 Free PMC article. No abstract available.

5

Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.

Harbeck N, Untch M, Pache L, Eiermann W. Harbeck N, et al. Br J Cancer. 1994 Mar;69(3):566-71. doi: 10.1038/bjc.1994.103. Br J Cancer. 1994. PMID: 7510120 Free PMC article.

6

Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.

Braun S, Harbeck N. Braun S, et al. Among authors: harbeck n. Breast Cancer Res. 2001;3(5):285-8. doi: 10.1186/bcr308. Epub 2001 Jun 28. Breast Cancer Res. 2001. PMID: 11597315 Free PMC article. Review.

7

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

8

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

9

Human kallikrein 8, a novel biomarker for ovarian carcinoma.

Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP. Kishi T, et al. Among authors: harbeck n. Cancer Res. 2003 Jun 1;63(11):2771-4. Cancer Res. 2003. PMID: 12782581

10

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Harbeck N, et al. Clin Breast Cancer. 2004 Dec;5(5):348-52. doi: 10.3816/cbc.2004.n.040. Clin Breast Cancer. 2004. PMID: 15585071 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

692 results

Search Page